Sunday, August 5, 2012

FDA to review Medivation, Astellas' prostate cancer drug in November

(Reuters) - Medivation Inc and Japanese partner Astellas Pharma Inc said the U.S. health regulator has set an action date of November 22 to review the companies' marketing application for their experimental prostate cancer drug.

monitoring remote pc remote equipment monitoring first alert canada

No comments:

Post a Comment